Aclaris Therapeutics (ACRS) Accumulated Expenses (2014 - 2026)

Aclaris Therapeutics' Accumulated Expenses history runs 13 years deep, the most recent figure standing at $5.9 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 31.22% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $5.9 million (down 31.22% YoY), while the FY2025 annual figure was $8.8 million, up 76.56% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $5.9 million, down from $8.8 million in the prior quarter.
• The five-year high for Accumulated Expenses was $9.2 million in Q3 2022, with the low at $2.6 million in Q1 2024.
• The 5-year median for Accumulated Expenses is $5.0 million (2023), against an average of $4.9 million.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses sank 58.38% in 2022, then jumped 231.22% in 2025.
• Aclaris Therapeutics' Accumulated Expenses stood at $5.3 million in 2022, then slipped by 26.16% to $3.9 million in 2023, then grew by 27.34% to $5.0 million in 2024, then jumped by 76.56% to $8.8 million in 2025, then slumped by 32.93% to $5.9 million in 2026.
• Business Quant data shows ACRS's Accumulated Expenses at $5.9 million in Q1 2026, $8.8 million in Q4 2025, and $3.8 million in Q3 2025.